Source: Annual Congress 2013 –COPD biomarkers
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Pertseva, K. Gashynova, O. Bratus, N. Petrik (Dnipropetrovsk, Ukraine). Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE). Eur Respir J 2013; 42: Suppl. 57, 2175

Member's Comments

Gunnar Husebø (Fana, Norway) - 07.09.2013 00:10
Meget bra!

Related content which might interest you: The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP) Source: International Congress 2014 – Clinical presentations Year: 2014 Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes Source: International Congress 2015 – Different data in COPD Year: 2015 COPD: Plasma surfactant protein-D (SPD) concentration as a predictor of acute exacerbations (AE) probability Source: International Congress 2016 – Features and impact of comorbidities in COPD Year: 2016 Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level Source: International Congress 2014 – COPD markers Year: 2014 COPD: Acute exacerbation (AE) rate and saturation in the patients with different plasma surfactant protein D (SP-D) level Source: Annual Congress 2013 –COPD mechanisms Year: 2013 CAT in COPD phenotypes (POPE study) Source: International Congress 2016 – Phenotyping and monitoring airway diseases Year: 2016 Co-morbidity and hospitalization rate in patients (pts) with acute exacerbation (AE) of COPD Source: International Congress 2015 – Different data in COPD Year: 2015 LSC - 2019 - Plasma surfactant protein-D (SP-D) as a predictor of COPD severe acute exacerbation (SAE) Source: International Congress 2019 – Exacerbations of airway diseases Year: 2019 COPD: Acute exacerbation (AE) and hospitalization rate (HR) in patients with different serum surfactant protein D (SPD) level Source: Annual Congress 2012 - COPD exacerbation Year: 2012 Heterogeneity inside group D COPD patients: About 827 cases Source: International Congress 2016 – Biomarkers and phenotypes of COPD Year: 2016 Plasma surfactant protein D (SP-D) and comorbidity rate in patients with COPD Source: International Congress 2014 – Predictors Year: 2014 Vascular-platelet hemostasis parameters in the stable phase and in acute exacerbation (AE) of COPD Source: International Congress 2015 – COPD: exacerbations, gas exchange and associated dysfunction Year: 2015 Serum SP-A and SP-D levels in patients admitted to the hospital with acute COPD exacerbation Source: International Congress 2016 – Inflammatory biomarkers in airway diseases Year: 2016 Plasma surfactant protein-D (SPD) concentration and severity of airflow limitation in COPD patients (pts) Source: International Congress 2016 – Biomarkers and phenotypes of COPD Year: 2016 Study on the relation between serum complement (C3, C4) levels and acute exacerbations in patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2008 - Biomarkers and disease assessment in COPD Year: 2008 The estimation of respiratory muscles (RM) status by echodensitometry in male patients with acute exacerbation of COPD (AECOPD) Source: Annual Congress 2010 - Interaction between respiratory and peripheral muscles Year: 2010 Increased circulating alveolar epithelial microparticles in COPD patients Source: International Congress 2015 – Modulating the immune system in COPD and asthma Year: 2015 Altered expression of glycosaminoglycans in the BAL of COPD patients with acute exacerbation Source: Annual Congress 2013 –Translational studies in chronic lung diseases: from bedside to bench Year: 2013 The serum level of surfactantproteind in patients with chronic obstructive pulmonary disease, depending on the nutrtional status Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD Year: 2015 Efficacy of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) on exacerbations and health status in GOLD Group D COPD patients: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016